Similarly, limited evidence from a substudy found that although eplerenone was associated with higher mean utility score (indicating better health-related quality of life) than standard therapy alone at 12 months, the difference did not reach statistical significance.
← all excerpts
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.
1
—
—